Match!

Is technology integration the solution to biotechnology's low research and development productivity?

Published on May 1, 2006in Technovation5.25
· DOI :10.1016/j.technovation.2005.06.001
Arsia Amir-Aslani2
Estimated H-index: 2
(University of Paris),
Syoum Negassi4
Estimated H-index: 4
(University of Paris)
Cite
Abstract
Abstract The demand for innovative and cost-effective products has had considerable impact on the Research and Development (R&D) portfolio of pharmaceutical companies. With the advent of the new enabling technologies, the biotechnology revolution has created a need for a new and more appropriate paradigm for drug development. The progress in the biological understanding of disease processes and related technological developments have been a major step forward for drug discovery. However, the great majority of the biotechnology companies are confronted with the same issues as major pharmaceutical companies in terms of R&D productivity. This article intends to unfold the challenges faced by biotechnology companies involved in drug discovery by managing the complexity, uncertainty and urgency of technology integration through organic, acquisition and partnering strategies have become priorities for biotechnology companies in helping them achieving more efficiency in their pharmaceutical R&D efforts. Such strategies help biotechnology companies apply their technologies across a broad range of applications within the drug discovery value chain to maximize opportunities for product development. Competitive advantage in the marketplace ultimately derives from providing better speed, cost, quality and direction.
  • References (21)
  • Citations (40)
Cite
References21
Newest
Published on May 1, 2004in Nature Reviews Drug Discovery57.62
Michael Dickson10
Estimated H-index: 10
(USC: University of South Carolina),
Jean Paul Gagnon2
Estimated H-index: 2
(Aventis Pharma)
The development of a new drug requires a major investment of capital, human resources and technological expertise. It also requires strict compliance with regulations on testing and manufacturing standards before a new compound can be used in the general population. All these requirements contribute to the cost increases for new chemical entity (NCE) R&D. The central question raised by this trend is: who in the future will pay for new pharmaceutical R&D? With this question in mind, this article ...
Published on Dec 1, 2003in Drug Discovery Today6.88
David Brown4
Estimated H-index: 4
(University of Hertfordshire),
Giulio Superti-Furga73
Estimated H-index: 73
Advances over the past decade in drug discovery technologies have not yet led to an increase in productivity. We analyzed the reasons that have led to this juncture and identify the selection of the right target and the right lead as crucial. New approaches are required to take full advantage of the genomics revolution. For targets, methods are becoming available for high-throughput proteome analysis and pathway characterization that synergize with studies of disease association and differential...
Published on Oct 1, 2003in Drug Discovery Today6.88
John S. Beattie8
Estimated H-index: 8
,
Peter Ghazal39
Estimated H-index: 39
Published on Aug 21, 2003in The New England Journal of Medicine70.67
Steffie Woolhandler49
Estimated H-index: 49
(Harvard University),
Terry Campbell3
Estimated H-index: 3
(Harvard University),
David U. Himmelstein50
Estimated H-index: 50
(Harvard University)
background A decade ago, the administrative costs of health care in the United States greatly exceeded those in Canada. We investigated whether the ascendancy of computerization, managed care, and the adoption of more businesslike approaches to health care have decreased administrative costs. methods For the United States and Canada, we calculated the administrative costs of health insurers, employers’ health benefit programs, hospitals, practitioners’ offices, nursing homes, and home care agenc...
Published on Aug 1, 2003in Nature Biotechnology31.86
Gary Walsh23
Estimated H-index: 23
Published on Aug 1, 2003in Trends in Biotechnology13.75
Denis Noble68
Estimated H-index: 68
(University of Oxford)
The successful identification of drug targets requires an understanding of the high-level functional interactions between the key components of cells, organs and systems, and how these interactions change in disease states. This information does not reside in the genome, or in the individual proteins that genes code for, it is to be found at a higher level. Genomics will succeed in revolutionising pharmaceutical research and development only if these interactions are also understood by determini...
Published on Jun 1, 2003in Nature Biotechnology31.86
Mark G Edwards2
Estimated H-index: 2
,
Fiona Murray23
Estimated H-index: 23
(MIT: Massachusetts Institute of Technology),
Robert Yu2
Estimated H-index: 2
An analysis of deal structures in biotechnology from the past 25 years reveals that universities often neglect important economic aspects in their licensing agreements.
Published on May 1, 2003in Drug Discovery Today6.88
Jürgen Drews2
Estimated H-index: 2
(Bear Stearns)
Abstract The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery: the search for disease-related targets, and the study of drug–protein interactions and protein–protein interactions. The first tier of the biotechnology industry has now become the most prod...
Published on Feb 1, 2003in Oncologist5.25
Robert A. Ingram1
Estimated H-index: 1
Cited By40
Newest
Published on Apr 1, 2019in Journal of Small Business Management3.12
Tianjiao Xia4
Estimated H-index: 4
(Lboro: Loughborough University),
Dimo Dimov23
Estimated H-index: 23
Engaging in exploration and exploitation is essential to business survival and performance. While firms manage exploration and exploitation alliances for the long-term, how prepared are they for sudden shocks in the short-term? We address this question in the context of a unique and opportune natural experiment associated with the 2008 financial crisis. Our analysis of 155 new biopharmaceutical ventures over a seven-year period suggests that exploration alliances – with a long-term orientation –...
John Kopano Mashala (TUT: Tshwane University of Technology), David Kruger2
Estimated H-index: 2
(UNISA: University of South Africa)
+ 1 AuthorsL. Steynberg3
Estimated H-index: 3
(TUT: Tshwane University of Technology)
This research article profiles cotton technology in the Makhathini region, focusing on the extent to which it is available to support farmers Although Makhathini Farmers have produced cotton for more than 10 years at a subsistence level, and despite using the related technology extensively, the farmers’ mission remains to produce cotton commercial. The technology mentioned in the study is available worldwide, as well as locally. The technology accessed is readily available to the local farmers. ...
Published on Aug 1, 2017in IEEE Transactions on Engineering Management1.87
Nazrul Islam15
Estimated H-index: 15
(University of Exeter)
The paper develops an integrated technology-push and market-pull framework, a value chain model for crossing the valley of death (VOD—the gap between laboratory and market) for emerging technologies based on primary and secondary data analyses, and a survey conducted on European research and development projects. The study uses a case of micro- and nano-manufacturing technology (MNT), and confirms the existence of the VOD through the survey data analysis. A mixed-methods approach was adopted tha...
Published on Feb 23, 2017in PLOS ONE2.78
Kenneth Fernald3
Estimated H-index: 3
(EUR: Erasmus University Rotterdam),
Enrico Pennings19
Estimated H-index: 19
(EUR: Erasmus University Rotterdam)
+ 2 AuthorsEric Claassen34
Estimated H-index: 34
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innovation activities of Big Pharma firms. The study indicates a rising interest of Big Pharma in acquisitions of and alliances with biotechnology companies. Unfortunately, this increased interest is not reflected in the number of new drugs generated by Big Pharma. We find that acquisitions of biotech com...
Published on Sep 1, 2016in Journal of Product Innovation Management3.78
Dandan Liu4
Estimated H-index: 4
,
Xiaoling Pu1
Estimated H-index: 1
,
Mary E. Schramm1
Estimated H-index: 1
(Quinnipiac University)
Traditionally, firms in the pharmaceutical industry have depended on their internal research and development (R&D) capabilities to maintain a productive new product pipeline. During the past two decades, however, the industry's pipeline productivity has decreased compromising the industry's ability to meet shareholder expectations. As a strategy to invigorate pipeline productivity, and impact financial performance, pharmaceutical firms have increased utilization of strategic technical alliances....
Published on Jan 1, 2016
Andrea Signori7
Estimated H-index: 7
(University of Milan)
This study addresses the signaling power of corporate innovation indicators in the IPO market. Innovation measures can convey considerably different signals to public investors, depending on whether they quantify the firm’s commitment in innovative inputs, as in the case of R&D investments, or achieved outputs, as in the case of patents. This study aims at disentangling such effects. Using a sample of 382 high-tech entrepreneurial firms going public in Europe during 1998–2003, this paper studies...
Published on Dec 10, 2015
Kenneth Fernald1
Estimated H-index: 1
markdownabstractAbstract Improving medicine and health is the ultimate purpose of biotechnological innovation, where basic science is used to develop new innovative diagnostics and therapeutics to significantly improve the lives of patients worldwide. Concurrently, for three stakeholder groups, the primary goal is to generate profitable business from biotechnological innovation. These stakeholders are ‘entrepreneurial’ biotech companies, venture capitalists and established pharmaceutical firms. ...
Published on Apr 17, 2015
Rahul Rekhi2
Estimated H-index: 2
,
David Thomas Ryan1
Estimated H-index: 1
+ 2 AuthorsAmina A. Qutub1
Estimated H-index: 1
Published on Jan 1, 2015in Global Journal of Health Science
Joseph Feulefack1
Estimated H-index: 1
,
Consolato Sergi24
Estimated H-index: 24
(U of A: University of Alberta)
A systematic literature review on pharmaceutical companies may be a tool for guiding some procedures of RD such as reliability of companies on “sourcing-in” R&D facilities and “think-tank” events. Regardless of the study and of the country, cash flow and profitability always positively influenced R&D expenditure, while sales and firm size did not. We consider that handling R&D determinants should require caution. It seems critical that implementation of R&D systems is directly related with produ...
Published on Dec 1, 2013in European Journal of Futures Research
Matti Pihlajamaa3
Estimated H-index: 3
(Aalto University),
Anne Sisko Patana2
Estimated H-index: 2
(Aalto University)
+ 1 AuthorsLaura Kanto2
Estimated H-index: 2
(Aalto University)
Innovation policy can never be fully technology-neutral and policies often align to support incumbent technological regimes obstructing the development of new industries. In this paper, two fields are analyzed: the life sciences industry and the solar energy industry to evaluate the Finnish innovation policy’s capabilities to promote emerging industries. Qualitative research methods are used for this exploratory study. The data consists of 29 semi-structured interviews and two workshops. The int...
View next paperAbsorptive Capacity: A New Perspective on Learning and Innovation